Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) has been given a consensus rating of “Moderate Buy” by the thirteen brokerages that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eleven have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $40.60.
Several equities analysts have issued reports on the stock. JPMorgan Chase & Co. cut their price target on shares of Olema Pharmaceuticals from $52.00 to $46.00 and set an “overweight” rating on the stock in a report on Thursday, August 13th. HC Wainwright decreased their price objective on Olema Pharmaceuticals from $38.00 to $36.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. Citigroup lowered their price objective on Olema Pharmaceuticals to $59.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. Wall Street Zen cut Olema Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 25th. Finally, Weiss Ratings upgraded Olema Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, September 21st.
Get Our Latest Stock Analysis on Olema Pharmaceuticals
Olema Pharmaceuticals Stock Down 6.5%
Olema Pharmaceuticals (NASDAQ:OLMA – Get Free Report) last posted its earnings results on Tuesday, November 10th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.09). On average, sell-side analysts predict that Olema Pharmaceuticals will post -2.42 EPS for the current fiscal year.
Institutional Investors Weigh In On Olema Pharmaceuticals
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Readystate Asset Management LP purchased a new stake in shares of Olema Pharmaceuticals during the second quarter worth about $7,429,000. Bank of America Corp DE acquired a new position in shares of Olema Pharmaceuticals during the second quarter valued at about $4,189,000. Siren L.L.C. raised its position in shares of Olema Pharmaceuticals by 44.1% in the 1st quarter. Siren L.L.C. now owns 4,756,949 shares of the company’s stock valued at $70,926,000 after purchasing an additional 1,456,249 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Olema Pharmaceuticals in the 2nd quarter valued at approximately $2,779,000. Finally, Defilade Capital Management L.P. boosted its stake in Olema Pharmaceuticals by 21.9% in the 1st quarter. Defilade Capital Management L.P. now owns 1,504,536 shares of the company’s stock worth $22,433,000 after purchasing an additional 269,902 shares in the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.
Olema Pharmaceuticals Company Profile
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for women’s cancers, particularly breast cancer. The company’s research centers on treatments that target pathways involved in hormone-sensitive tumors. Its lead candidate, palazestrant (OP-1250), is an oral therapy designed to act as both a selective estrogen receptor degrader and a complete estrogen receptor antagonist. Olema has studied it as a potential treatment for estrogen receptor–positive breast cancer, including in combination with other cancer medicines.
See Also
- Five stocks we like better than Olema Pharmaceuticals
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Olema Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olema Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
